Skip to content

SANGUI BIOTECH INTERNATIONAL INC: 10-Q filed 2019-05-13

What SANGUI BIOTECH INTERNATIONAL INC reported in its quarterly report filed 2019-05-13 (fiscal Q3 2019): 22 published measures, 63 facts as tagged in accession 0001551163-19-000118.

This filing

Form
10-Q (quarterly report)
Filed
2019-05-13
Fiscal period
fiscal Q3 2019
Accession
0001551163-19-000118 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SANGUI BIOTECH INTERNATIONAL INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-03-3150,762USD
At 2018-06-30102,029USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-03-31-478,318USD
At 2018-06-30-351,144USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-03-3118,529USD
At 2018-06-3020,943USD
At 2018-03-3124,151USD
At 2017-06-3056,990USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-01-01 to 2019-03-31-74,373USD90
2018-07-01 to 2019-03-31-230,316USD274
2018-01-01 to 2018-03-31-85,161USD90
2017-07-01 to 2018-03-31-232,875USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-07-01 to 2019-03-31-236,388USD274
2017-07-01 to 2018-03-31-184,009USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2019-01-01 to 2019-03-318,062USD90
2018-07-01 to 2019-03-3163,429USD274
2018-01-01 to 2018-03-3110,191USD90
2017-07-01 to 2018-03-3165,273USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-07-01 to 2019-03-31236,138USD274
2017-07-01 to 2018-03-31179,041USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-03-31-37,392,841USD
At 2018-06-30-37,180,108USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-03-31-74,150USD90
2018-07-01 to 2019-03-31-227,785USD274
2018-01-01 to 2018-03-31-68,798USD90
2017-07-01 to 2018-03-31-177,923USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-03-3150,762USD
At 2018-06-30102,029USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-01-01 to 2019-03-31-2,508USD90
2018-07-01 to 2019-03-31-8,724USD274
2018-01-01 to 2018-03-31-2,205USD90
2017-07-01 to 2018-03-31-5,981USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-03-31529,080USD
At 2018-06-30453,173USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-01-01 to 2019-03-3182,311USD90
2018-07-01 to 2019-03-31291,214USD274
2018-01-01 to 2018-03-3178,989USD90
2017-07-01 to 2018-03-31243,152USD274

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2019-01-01 to 2019-03-318,161USD90
2018-07-01 to 2019-03-3163,429USD274
2018-01-01 to 2018-03-3110,191USD90
2017-07-01 to 2018-03-3165,229USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-01-01 to 2019-03-315,092USD90
2018-07-01 to 2019-03-3120,378USD274
2018-01-01 to 2018-03-319,983USD90
2017-07-01 to 2018-03-3117,788USD274

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-03-314,513,328USD
At 2018-06-304,513,328USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2019-03-3188,338USD
At 2018-06-3092,921USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2018-07-01 to 2019-03-31-225,733USD274
2017-07-01 to 2018-03-31-195,764USD274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2019-01-01 to 2019-03-31-66,413USD90
2018-07-01 to 2019-03-31-212,732USD274
2018-01-01 to 2018-03-31-71,886USD90
2017-07-01 to 2018-03-31-184,768USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-01-01 to 2019-03-3137,519USD90
2018-07-01 to 2019-03-31127,920USD274
2018-01-01 to 2018-03-3134,140USD90
2017-07-01 to 2018-03-3196,575USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-07-01 to 2019-03-3184,491USD274
2017-07-01 to 2018-03-3188,928USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2018-07-01 to 2019-03-3138,125USD274

Inspect the source

Entity
SANGUI BIOTECH INTERNATIONAL INC / CIK 0001104280
Captured
SEC response SHA-256
80929a3d07bdd3be99cfb5858d464edb9844d0e622d958ee5dce9515baeeed6f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001104280.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))